Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones October 20, 2025 CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025 - Read More October 17, 2025 CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO - Read More September 30, 2025 CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC - Read More Load MoreLoadingMeet us at the following conferences & events 8th Cancer Cachexia Conference 2025 Sep 25 - Sep 27 Turin, Italy Read More ESMO Congress 2025 Oct 17 - Oct 21, 2025 Berlin, Germany Read More 40th SITC Annual Meeting 2025 Nov 5 - Nov 9, 2025 National Harbor, Maryland, USA Read More
